Liting Wang
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
-
- RNA Interference and Gene Delivery 4
-
- Nanoplatforms for cancer theranostics 12
- Co-authors
- Yourong Duan (19 shared papers)Fwu‐Ling Lee (1 shared paper)Hiroaki Kasai (1 shared paper)Feifei Yu (1 shared paper)Xiaotong Li (1 shared paper)Qianqian Guo (6 shared papers)Chuanrong Chen (11 shared papers)Zhihua Wu (9 shared papers)
- Journals
- Advances in Therapy (5 papers)Biomaterials (5 papers)Advanced Healthcare Materials (3 papers)European Journal of Medicinal Chemistry (3 papers)Advanced Science (3 papers)
- Partner nations
- ChinaTaiwanUnited States
In The Last Decade
Liting Wang
139 papers receiving 2.8k citations
Liting Wang's Hit Papers
Peers
Comparison fields: 5 of 160
- Cancer Research 236
- Biomaterials 225
- Molecular Biology 893
- Biomedical Engineering 556
- Immunology 231
Countries citing papers authored by Liting Wang
This map shows the geographic impact of Liting Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liting Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liting Wang more than expected).
Fields of papers citing papers by Liting Wang
This network shows the impact of papers produced by Liting Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liting Wang. The network helps show where Liting Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Liting Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 151 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 253 | |
| 2 | Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer Hit paper breakdown → | 2022 | 172 |
| 3 | 2020 | 137 | |
| 4 | 2013 | 101 | |
| 5 | 2022 | 93 | |
| 6 | 2019 | 83 | |
| 7 | 2014 | 76 | |
| 8 | 2023 | 76 | |
| 9 | 2021 | 64 | |
| 10 | 2010 | 59 | |
| 11 | 2018 | 59 | |
| 12 | 2013 | 58 | |
| 13 | 2020 | 57 | |
| 14 | 2016 | 55 | |
| 15 | 2019 | 47 | |
| 16 | 2022 | 45 | |
| 17 | 2016 | 42 | |
| 18 | 2021 | 41 | |
| 19 | 2019 | 40 | |
| 20 | 2023 | 36 |
About Liting Wang
Liting Wang is a scholar working on Molecular Biology, Biomedical Engineering, Oncology, Immunology and Electrical and Electronic Engineering, having authored 151 papers that have together received 2.9k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (12 papers), Conducting polymers and applications (6 papers), Nanoparticle-Based Drug Delivery (6 papers), Immunotherapy and Immune Responses (5 papers), Autophagy in Disease and Therapy (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Advanced Photocatalysis Techniques (4 papers) and RNA Interference and Gene Delivery (4 papers). The work is most often cited by research in Cancer Research (236 citations), Biomaterials (225 citations), Molecular Biology (893 citations), Biomedical Engineering (556 citations) and Immunology (231 citations). Liting Wang has collaborated with scholars based in China, Taiwan and United States. Frequent co-authors include Yourong Duan, Fwu‐Ling Lee, Hiroaki Kasai, Feifei Yu, Xiaotong Li, Qianqian Guo, Chuanrong Chen, Zhihua Wu, Jiali Zhang and Kuo‐How Huang. Their work appears in journals such as Advances in Therapy, Biomaterials, Advanced Healthcare Materials, European Journal of Medicinal Chemistry and Advanced Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.